HCT116 Cell Culture, Proliferation and VEGF Release Assay
Wild type human colon carcinoma cells, HCT116 and null p53 HCT116, were generously gifted by Dr. Teresa Iuvone (Department of Pharmacology University Naples, Italy). Cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine. Cells were maintained at 37 °C with 5% CO2 until reaching 85%-90% confluency. Before treatments, cells were harvested by trypsin and re-suspended in Hanks balanced salt solution (HBSS) without calcium or magnesium. Both cells type were incubated for 48 h with increasing concentrations of S100B (0.05-5 μM) in the presence of S100BmAb (1:10 5 and 1:10 4 v/v diluted). In the same experimental protocol, the effect of S100BmAb (1:10 4 v/v diluted) alone was also evaluated and the effect of RAGEmAb (1:10 4 v/v diluted) and SB203580 (10 M) was also tested in the presence of S100B (5 M) stimulus. As previously described, cell proliferation was evaluated by performing a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay [41] . Cell proliferation in response to treatments was calculated using the following equation: Cell proliferation at 48 h (%) = (OD treated / OD untreated) × 100. Enzyme-linked immunosorbent assay for human VEGF (Abcam, Cambridge, UK) was carried out on both HUVEC, wt and p53 null HCT116 cell supernatant after treatments at 24 h according to the manufacturer's protocol. Absorbance was measured on a microtiter plate reader. VEGF levels were thus determined using the standard curves method. as mean ± SEM of n = 6 experiments performed in triplicate.* p < 0.05; ** p < 0.01 and *** p < 0.001 versus vehicle; ° p < 0.05, °° p < 0.01 and °°° p < 0.001 versus S100B 5 M; # p < 0.05; § p < 0.05, respectively versus S100B 5 M -treated cells. Scale bar: 100 µ m. Magnification10X.
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